COMPARISON
Glucagon vs Tirzepatide
5 attributes held for at least one of the two. 4 differ. Each value carries the register it came from and the date that register was read.
Answer
Glucagon is authorised or registered in 10 and Tirzepatide in 10 of the 10 registers read. Glucagon: highest phase Phase 4 (after approval). Tirzepatide: highest phase Phase 4 (after approval). 234 registered trials include both.
States no view on which is preferable, safer or more effective. Not medical advice.
| Glucagon | Tirzepatide | |
|---|---|---|
| Registered trials differs | 1514 clinicaltrials.gov · 2026-10-03 | 309 clinicaltrials.gov · 2026-10-03 |
| FDA label differs | FDA-approved: Glucagon openfda · 2026-10-03T17:23:44.062Z | FDA-approved: MOUNJARO openfda · 2026-10-03T17:23:44.062Z |
| EU authorisation | Authorised ema · 2026-10-03 | Authorised ema · 2026-10-03 |
| EU authorised on differs | 2019-12-16 ema · 2026-10-03 | 2022-09-15 ema · 2026-10-03 |
| ATC code differs | H04AA01 ema · 2026-10-03 | A10BX16 ema · 2026-10-03 |
SIDE EFFECTS
Most common side effects, each beside its own placebo
| Side effect | Glucagon | placebo | Tirzepatide | placebo |
|---|---|---|---|---|
| Nausea | - | - | 25.6% | 8.1% |
| Diarrhoea | - | - | 21.2% | 8.3% |
| Covid-19 | - | - | 15.5% | 16.0% |
| Constipation | - | - | 13.7% | 4.5% |
| Decreased appetite | - | - | 11.6% | 2.9% |
| Vomiting | - | - | 11.4% | 2.6% |
| Dyspepsia | - | - | 7.9% | 2.7% |
| Headache | - | - | 6.6% | 6.2% |
| Abdominal pain | - | - | 6.0% | 2.7% |
| Upper respiratory tract infection | - | - | 5.7% | 6.2% |
Trial register Glucagon: 2 placebo-controlled trials; Tirzepatide: 19. Each peptide is compared with placebo in its own trials, not with the other: a dash means the event is not in that peptide's top list. Glucagon side effects · Tirzepatide side effects
LEGAL STATUS
Approval in each country read
| Country | Glucagon | Tirzepatide | Register |
|---|---|---|---|
| United States | FDA-approved | FDA-approved | Regulator FDA |
| European Union | Authorised | Authorised | Regulator EMA |
| United Kingdom | Authorised | Authorised | Regulator MHRA |
| Canada | Authorised | Authorised | Regulator Health Canada |
| Australia | Registered | Registered | Regulator TGA |
| Switzerland | Authorised | Authorised | Regulator Swissmedic |
| Brazil | Registado | Registado | Regulator ANVISA |
| Serbia | Authorised | Authorised | Regulator ALIMS |
| Singapore | Registered | Registered | Regulator HSA |
| Turkey | Ruhsatli | Ruhsatli | Regulator TITCK |
HEAD TO HEAD
234 registered trials include both
| NCT06861439 | GLP-1s to Enhance Lasting Optimal Weight ACTIVE_NOT_RECRUITING · updated 2026-10-02 |
|---|---|
| NCT07065552 | Tirzepatide in Obesity-Driven Endometrial Cancer RECRUITING · updated 2026-10-02 |
| NCT07734792 | Tirzepatide in Thrombectomy-Treated Acute Ischemic Stroke: A Randomized Trial NOT_YET_RECRUITING · updated 2026-10-01 |
| NCT06603571 | A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight W COMPLETED · updated 2026-09-29 |
| NCT07527910 | A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD RECRUITING · updated 2026-09-29 |
| NCT06745128 | Tirzepatide for Obesity and Meth Use Disorder COMPLETED · updated 2026-09-28 |
| NCT07078838 | Tirzepatide in Women With Obesity and Endometrial Intra-epithelial Neoplasia or Grade 1 Endometrial Cancer NOT_YET_RECRUITING · updated 2026-09-28 |
| NCT06700538 | A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes Mellitus RECRUITING · updated 2026-09-25 |
| NCT06759701 | Pre-Surgical Tirzepatide-Assisted Weight Loss in Overweight and Obese Men With Intermediate Risk Prostate Cancer: A Pilot Feasibility Study RECRUITING · updated 2026-09-25 |
| NCT06439277 | A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2) RECRUITING · updated 2026-09-24 |
| NCT06937086 | Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: RECRUITING · updated 2026-09-24 |
| NCT06937099 | Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight RECRUITING · updated 2026-09-24 |
| NCT07265752 | Tirzepatide for the Treatment of Cannabis Use Disorder NOT_YET_RECRUITING · updated 2026-09-24 |
| NCT07734870 | Tirzepatide for Treatment of CCCA RECRUITING · updated 2026-09-23 |
| NCT05556512 | A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity ACTIVE_NOT_RECRUITING · updated 2026-09-22 |
| NCT07165028 | A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) RECRUITING · updated 2026-09-22 |
| NCT06734273 | Randomized Control Trial of Sleeve Gastrectomy With Tirzepatide in Maximizing Weight Loss ACTIVE_NOT_RECRUITING · updated 2026-09-21 |
| NCT06864026 | A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity ACTIVE_NOT_RECRUITING · updated 2026-09-21 |
| NCT07468552 | Trial of Tirzepatide for the Treatment of Cannabis Use Disorder NOT_YET_RECRUITING · updated 2026-09-21 |
| NCT06779929 | Comparative Study of Tirzepatide Versus Dulaglutide (SURPASS CVOT) or Semaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes COMPLETED · updated 2026-09-18 |
The 20 most recently updated are listed.
Values reproduce public registers on the dates shown. This comparison states no view on which compound is preferable, safer or more effective. Not medical, legal or regulatory advice.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.